1. Corvol, Harriet, Mésinèle, Julie, Douksieh, Isman-Hassan, Boëlle, Pierre-Yves, Guillot, Loïc. 2018. SLC26A9 Gene Is Associated With Lung Function Response to Ivacaftor in Patients With Cystic Fibrosis. In Frontiers in pharmacology, 9, 828. doi:10.3389/fphar.2018.00828. https://pubmed.ncbi.nlm.nih.gov/30140228/
2. Strug, Lisa J, Gonska, Tanja, He, Gengming, Bear, Christine E, Rommens, Johanna M. . Cystic fibrosis gene modifier SLC26A9 modulates airway response to CFTR-directed therapeutics. In Human molecular genetics, 25, 4590-4600. doi:10.1093/hmg/ddw290. https://pubmed.ncbi.nlm.nih.gov/28171547/
3. Lam, Anh-Thu N, Aksit, Melis A, Vecchio-Pagan, Briana, Blackman, Scott M, Cutting, Garry R. . Increased expression of anion transporter SLC26A9 delays diabetes onset in cystic fibrosis. In The Journal of clinical investigation, 130, 272-286. doi:10.1172/JCI129833. https://pubmed.ncbi.nlm.nih.gov/31581148/
4. Bakouh, Naziha, Bienvenu, Thierry, Thomas, Annick, Planelles, Gabrielle, Sermet-Gaudelus, Isabelle. 2013. Characterization of SLC26A9 in patients with CF-like lung disease. In Human mutation, 34, 1404-14. doi:10.1002/humu.22382. https://pubmed.ncbi.nlm.nih.gov/24272871/
5. Sato, Yukiko, Thomas, David Y, Hanrahan, John W. 2019. The anion transporter SLC26A9 localizes to tight junctions and is degraded by the proteasome when co-expressed with F508del-CFTR. In The Journal of biological chemistry, 294, 18269-18284. doi:10.1074/jbc.RA119.010192. https://pubmed.ncbi.nlm.nih.gov/31645438/
智鼠故事 
